Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | ATP4A | P20648 | 1/20 | 0.31 |
| ▸ | ATP4B | P51164 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407599 | 1.00 | HSD17B1 (0.36) | HSD17B1HSD17B2IDH1JAK2ATP4A | |
| SCHEMBL2410202 | 0.86 | CYP2A6 (0.35) | NPC1RAB9AALDH1A1HPGDHTT | |
| SCHEMBL2410199 | 0.86 | CYP2A6 (0.35) | NPC1RAB9AALDH1A1HPGDHTT | |
| SCHEMBL2414216 | 0.84 | CNR1 (0.38) | ATP4AATP4BNPC1RAB9AALDH1A1 | |
| SCHEMBL2414214 | 0.84 | CNR1 (0.38) | ATP4AATP4BNPC1RAB9AALDH1A1 | |
| SCHEMBL2413297 | 0.83 | ADORA3 (0.37) | HSD17B1HSD17B2 | |
| SCHEMBL2413299 | 0.83 | ADORA3 (0.37) | HSD17B1HSD17B2 | |
| SCHEMBL2409726 | 0.82 | PRMT5 (0.38) | NPC1RAB9AHPGDHTTSMN1; SMN2 | |
| SCHEMBL2409730 | 0.82 | PRMT5 (0.38) | NPC1RAB9AHPGDHTTSMN1; SMN2 | |
| SCHEMBL2411194 | 0.81 | ROCK1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013010-B2 | 5-thioxylopyranose compounds | LABORATOIRES FOURNIER S.A. (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | LABORATOIRES FOURNIER S.A (FR) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186840-A1 | 5-Thioxylopyranose Compounds | TPMT, PNPO, CYP3A5 | HSD17B1 1048/4885HSD17B2 1172/4885IDH1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.